Toggle light / dark theme

Are pomegranates really the superfood we’ve been led to believe will counteract the aging process? Up to now, scientific proof has been fairly weak. And some controversial marketing tactics have led to skepticism as well. A team of scientists from EPFL and the company Amazentis wanted to explore the issue by taking a closer look at the secrets of this plump pink fruit. They discovered that a molecule in pomegranates, transformed by microbes in the gut, enables muscle cells to protect themselves against one of the major causes of aging. In nematodes and rodents, the effect is nothing short of amazing. Human clinical trials are currently underway, but these initial findings have already been published in the journal Nature Medicine.

As we age, our cells increasingly struggle to recycle their powerhouses. Called mitochondria, these inner compartments are no longer able to carry out their vital function, thus accumulate in the cell. This degradation affects the health of many tissues, including muscles, which gradually weaken over the years. A buildup of dysfunctional mitochondria is also suspected of playing a role in other diseases of aging, such as Parkinson’s disease.

One molecule plays David against the Goliath of aging

The scientists identified a molecule that, all by itself, managed to re-establish the cell’s ability to recycle the components of the : urolithin A. “It’s the only known molecule that can relaunch the mitochondrial clean-up process, otherwise known as mitophagy,” says Patrick Aebischer, co-author on the study. “It’s a completely natural substance, and its effect is powerful and measurable.”

Read more

Synthetic diamonds and the manufacturing of diamonds in mass quantity (including 3D Printing) is going to explode over the next few years with QC, Medical devices and technologies, smartphones, etc. Again, I hope Intel, Nvidia, HP, Xerox, etc. are listening.


Chicago-based startup Akhan Semiconducton wants to replace the silicon found in most modern-day electronics with diamonds derived from methane gas.

Read more

(NaturalNews) Earlier this month, Juno Therapeutics, a pioneer in the field of treating cancer using genetically engineered cells, had to halt the development of its lead treatment after the death of three leukemia patients enrolled in the study.

The Seattle-based biotech company reported that the deaths of all three patients, who were in their 20s, were linked to swelling in the brain. The swelling occurred after the company added a second chemotherapy drug to the treatment procedure.

The news of the patient deaths is a big blow for the biotech startup that is developing a new experimental therapy known as chimeric antigen receptor T-cell (or CART) immunotherapy. The setback will likely delay the company’s aim of introducing it to the market by 2017, Juno executives said in a conference.

Read more

They discovered that changes in the bone marrow needed for the cancer to grow have already taken hold in the preceding condition, raising the possibility that early medical intervention could prevent this incurable type of cancer from taking root.

The research, which was funded by the blood cancer charity Bloodwise, is published in the journal Leukemia.

Myeloma affects the plasma cells, a type of white blood cell that originates in the bone marrow. Diagnosed in over 4,000 people a year in the UK, fewer than half of patients survive for longer than five years after diagnosis. Symptoms often include debilitating and painful bone damage, anemia and nausea.

Read more

Nice callout of the Gates Foundation.


“Amaranth, Amaranto, love-lies-bleeding, tassel flower, Joseph’s coat, or ramdana (gods own grain) is the grain of well-being,” Shiva writes. (Photo: Elizabeth Weller/flickr/cc)

A recent report from the National Academy of Science of The United States, titled “Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values,” warns:

“One possible goal of release of a gene-drive modified organism is to cause the extinction of the target species or a drastic reduction in its abundance.”

Read more

Very cool; another example where nature inspires others. Einstein was inspired often by nature and its environment.


Titanium is used medically in applications such as artificial joints and dental implants. While it is strong and is not harmful to tissues, the metal lacks some of the beneficial biological properties of natural tissues such as bones and natural teeth. Now, based on insights from mussels—which are able to attach themselves very tightly to even metallic surfaces due to special proteins found in their byssal threads—scientists from RIKEN have successfully attached a biologically active molecule to a titanium surface, paving the way for implants that can be more biologically beneficial.

The work began from earlier discoveries that mussels can attach to smooth surfaces so effectively thanks to a protein, L-DOPA, which is known to be able to bind very strongly to smooth surfaces such as rocks, ceramics, or metals. Interestingly, the same protein functions in humans as a precursor to dopamine, and is used as a treatment for Parkinson’s disease.

Using a combination of recombinant DNA technology and treatment with tyrosinase, they were able to create a hybrid protein that contained active parts of both the growth factor and L-DOPA. Tests showed that the proteins were able to fold normally, and further experiments in cell cultures demonstrated that the IGF-1 was still functioning normally. Thanks to the incorporation of the L-DOPA, the team was able to confirm that the proteins bound strongly to the titanium surface, and remained attached even when the metal was washed with phosphate-buffered saline, a water-based solution. Zhang says, “This is similar to the powerful properties of mussel adhesive, which can remain fixed to metallic materials even underwater.”

Read more

Personally; I have heard this several years ago from some medical researchers. Glad that more have concluded this tie.


Genetic mutations on several genes including BRCA2 have been associated with prostate cancer; while in a separate study, a BRCA1 mutation has been linked to a particular form of uterine cancer.

The first study, published in the New England Journal of Medicine, found that 12 percent of men with advanced prostate cancer had inherited mutations in genes involved in the repair of damaged DNA.

Professor Johann de Bono of the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, who led the study, said: ‘Our study has shown that a significant proportion of men with advanced prostate cancer are born with DNA repair mutations – and this could have important implications for patients.

Read more

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will set up seven new Research Units and one new Clinical Research Unit. This was decided by the Senate of the DFG in its summer session during the DFG Annual Meeting in Mainz. In addition to the already established Units, another Research Unit is now in a position to start work. This Unit is funded jointly by the DFG and the Austrian Science Fund (FWF). The DFG Senate had already supported this Unit in March 2016 and approval has now been obtained from the Austrian partner organisation.

The research collaborations will offer researchers the possibility of pursuing current and pressing issues in their research areas and establishing innovative work directions. Clinical Research Units are also characterised by the close connection between research and clinical work. The maximum funding duration of Research Units and Clinical Research Units is two periods of three years. In the initial funding period, the nine new groups will receive approximately €23 million in total. As a result, the DFG will be funding a total of 190 Research Units and 19 Clinical Research Units.

The new Research Units.

Read more